Trade Summary

4 days ago, ORBIMED ADVISORS LLC, serving as 10% owner Owner at Enliven Therapeutics, Inc. (ELVN), sold 860,123 shares at $45.36 per share, for a total transaction value of $39,014,045.60. Following this transaction, ORBIMED ADVISORS LLC now holds 6,555,102 shares of ELVN.

This sale represents a 11.60% decrease in ORBIMED ADVISORS LLC's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Monday, June 22, 2026 and publicly disclosed via SEC Form 4 filing on Wednesday, June 24, 2026 at 7:19 PM ET, 2 days after the trade was made.

Enliven Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.